Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - ALL SCT BFM international

St. Anna Kinderkrebsforschung0 个研究点目标入组 405 人开始时间: 2007年1月11日最近更新: 2022年3月2日

适应症

试验速览

暂无简介。

•*Age at ALL diagnosis (for HSCT indication in CR1) or at ALL relapse diagnosis: =18 years
•*ALL in first, second or any following complete remission
•*Indication for allogeneic HSCT (see chapter Indications for allogeneic HSCT, page 11)
•*Signed informed consent of parents or legal guardian of the minor patient (and in certain cases the patient himself/herself) for participation in the study ALL SCT BFM international.
•*The patient is treated in a hospital participating in the study during the study period.
•*No evidence of pregnancy
•*No secondary malignancy
•*No history of allogeneic or autologous HSCT
•All patients who are entered into the study according to these criteria are study patients. Once registered into the study, a patient is only excluded from the study, if the diagnosis ALL turns out to be clearly wrong.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

发起方